Cdc20 inhibitor apcin inhibits the growth and invasion of osteosarcoma cells

  • Authors:
    • Yuan Gao
    • Benyuan Zhang
    • Yuming Wang
    • Guanning Shang
  • View Affiliations

  • Published online on: May 30, 2018     https://doi.org/10.3892/or.2018.6467
  • Pages: 841-848
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor worldwide, primarily affecting children and adolescents. The anaphase promoting complex/cyclosome (APC/C) is a ubiquitin ligase that is activated by its co‑activator Cdc20 during the metaphase‑anaphase transition. Apcin is a novel cell‑permeable molecule that blocks the interaction between APC/C and Cdc20. Cdc20 overexpression has been reported in various malignancies and plays an oncogenic role in tumorigenesis and tumor progression. In the present study, the antitumor properties of apcin, an inhibitor of Cdc20, was investigated in OS cell lines. In addition, the possible molecular target by which apcin mediates cell death was explored. Apcin was demonstrated to inhibit OS cell growth and induce significant apoptosis. The invasion and mobile abilities of OS cells were also markedly suppressed by apcin treatment. Furthermore, Bim and p21 were upregulated in OS cells following apcin treatment. The results of the present study indicated that apcin may have therapeutic potential as a treatment for OS and that Cdc20 may be a promising molecular target for chemotherapy.

References

1 

Shaikh AB, Li F, Li M, He B, He X, Chen G, Guo B, Li D, Jiang F, Dang L, et al: Present advances and future perspectives of molecular targeted therapy for osteosarcoma. Int J Mol Sci. 17:5062016. View Article : Google Scholar : PubMed/NCBI

2 

Zhou W, Hao M, Du X, Chen K, Wang G and Yang J: Advances in targeted therapy for osteosarcoma. Discov Med. 17:301–307. 2014.PubMed/NCBI

3 

Moore DD and Luu HH: Osteosarcoma. Cancer Treat Res. 162:65–92. 2014. View Article : Google Scholar : PubMed/NCBI

4 

Jones KB: Osteosarcomagenesis: Modeling cancer initiation in the mouse. Sarcoma. 2011:6941362011. View Article : Google Scholar : PubMed/NCBI

5 

Li X, Jiang H, Xiao L, Wang S and Zheng J: miR-200bc/429 inhibits osteosarcoma cell proliferation and invasion by targeting PMP22. Med Sci Monit. 23:1001–1008. 2017. View Article : Google Scholar : PubMed/NCBI

6 

Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C and Menendez LR: A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma. 2012:7048722012. View Article : Google Scholar : PubMed/NCBI

7 

Wu PK, Chen WM, Chen CF, Lee OK, Haung CK and Chen TH: Primary osteogenic sarcoma with pulmonary metastasis: Clinical results and prognostic factors in 91 patients. Jpn J Clin Oncol. 39:514–522. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI

9 

Nandi D, Tahiliani P, Kumar A and Chandu D: The ubiquitin-proteasome system. J Biosci. 31:137–155. 2006. View Article : Google Scholar : PubMed/NCBI

10 

Chang LF, Zhang Z, Yang J, McLaughlin SH and Barford D: Molecular architecture and mechanism of the anaphase-promoting complex. Nature. 513:388–393. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Passmore LA, McCormack EA, Au SW, Paul A, Willison KR, Harper JW and Barford D: Doc1 mediates the activity of the anaphase-promoting complex by contributing to substrate recognition. EMBO J. 22:786–796. 2003. View Article : Google Scholar : PubMed/NCBI

12 

Sewart K and Hauf S: Different functionality of Cdc20 binding sites within the mitotic checkpoint complex. Curr Biol. 27:1213–1220. 2017. View Article : Google Scholar : PubMed/NCBI

13 

Wang L, Zhang J, Wan L, Zhou X, Wang Z and Wei W: Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol Ther. 151:141–151. 2015. View Article : Google Scholar : PubMed/NCBI

14 

Paul D, Ghorai S, Dinesh US, Shetty P, Chattopadhyay S and Santra MK: Cdc20 directs proteasome-mediated degradation of the tumor suppressor SMAR1 in higher grades of cancer through the anaphase promoting complex. Cell Death Dis. 8:e28822017. View Article : Google Scholar : PubMed/NCBI

15 

Marucci G, Morandi L, Magrini E, Farnedi A, Franceschi E, Miglio R, Calò D, Pession A, Foschini MP and Eusebi V: Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch. 453:599–609. 2008. View Article : Google Scholar : PubMed/NCBI

16 

Mao Y, Li K, Lu L, Si-Tu J, Lu M and Gao X: Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy. Cancer Biomark. 16:351–358. 2016. View Article : Google Scholar : PubMed/NCBI

17 

Choi JW, Kim Y, Lee JH and Kim YS: High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer. Virchows Arch. 463:681–687. 2013. View Article : Google Scholar : PubMed/NCBI

18 

Kim Y, Choi JW, Lee JH and Kim YS: MAD2 and CDC20 are upregulated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the uterine cervix. Int J Gynecol Pathol. 33:517–523. 2014. View Article : Google Scholar : PubMed/NCBI

19 

Wu WJ, Hu KS, Wang DS, Zeng ZL, Zhang DS, Chen DL, Bai L and Xu RH: CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer. J Transl Med. 11:1422013. View Article : Google Scholar : PubMed/NCBI

20 

Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C and Wang H: Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol. 5:152012. View Article : Google Scholar : PubMed/NCBI

21 

Moura IM, Delgado ML, Silva PM, Lopes CA, do Amaral JB, Monteiro LS and Bousbaa H: High CDC20 expression is associated with poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med. 43:225–231. 2014. View Article : Google Scholar : PubMed/NCBI

22 

Ding ZY, Wu HR, Zhang JM, Huang GR and Ji DD: Expression characteristics of CDC20 in gastric cancer and its correlation with poor prognosis. Int J Clin Exp Pathol. 7:722–727. 2014.PubMed/NCBI

23 

Shi R, Sun Q, Sun J, Wang X, Xia W, Dong G, Wang A, Jiang F and Xu L: Cell division cycle 20 overexpression predicts poor prognosis for patients with lung adenocarcinoma. Tumour Biol. 39:10104283176922332017. View Article : Google Scholar : PubMed/NCBI

24 

Li K, Mao Y, Lu L, Hu C, Wang D, Si-Tu J, Lu M, Peng S, Qiu J and Gao X: Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel. Int J Oncol. 49:1679–1685. 2016. View Article : Google Scholar : PubMed/NCBI

25 

Zhang Y, Xue YB, Li H, Qiu D, Wang ZW and Tan SS: Inhibition of cell survival by curcumin is associated with downregulation of cell division cycle 20 (Cdc20) in pancreatic cancer cells. Nutrients. 9:E1092017. View Article : Google Scholar : PubMed/NCBI

26 

Sackton KL, Dimova N, Zeng X, Tian W, Zhang M, Sackton TB, Meaders J, Pfaff KL, Sigoillot F, Yu H, et al: Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C. Nature. 514:646–649. 2014. View Article : Google Scholar : PubMed/NCBI

27 

Lub S, Maes A, Maes K, De Veirman K, De Bruyne E, Menu E, Fostier K, Kassambara A, Moreaux J, Hose D, et al: Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. Oncotarget. 7:4062–4076. 2016. View Article : Google Scholar : PubMed/NCBI

28 

de Lange J, Faramarz A, Oostra AB, de Menezes RX, van der Meulen IH, Rooimans MA, Rockx DA, Brakenhoff RH, van Beusechem VW, King RW, et al: Defective sister chromatid cohesion is synthetically lethal with impaired APC/C function. Nat Commun. 6:83992015. View Article : Google Scholar : PubMed/NCBI

29 

Wachtel M and Schäfer BW: Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev. 36:318–327. 2010. View Article : Google Scholar : PubMed/NCBI

30 

Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC and Tap WD: Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 118:5888–5893. 2012. View Article : Google Scholar : PubMed/NCBI

31 

Maki RG: Ifosfamide in the neoadjuvant treatment of osteogenic sarcoma. J Clin Oncol. 30:2033–2035. 2012. View Article : Google Scholar : PubMed/NCBI

32 

Gayyed MF, El-Maqsoud NM, Tawfiek ER, El Gelany SA and Rahman MF: A comprehensive analysis of CDC20 overexpression in common malignant tumors from multiple organs: Its correlation with tumor grade and stage. Tumour Biol. 37:749–762. 2016. View Article : Google Scholar : PubMed/NCBI

33 

Shang G, Ma X and Lv G: Cell division cycle 20 promotes cell proliferation and invasion and inhibits apoptosis in osteosarcoma cells. Cell Cycle. 17:43–52. 2018. View Article : Google Scholar : PubMed/NCBI

34 

Das T, Roy KS, Chakrabarti T, Mukhopadhyay S and Roychoudhury S: Withaferin A modulates the Spindle assembly checkpoint by degradation of Mad2-Cdc20 complex in colorectal cancer cell lines. Biochem Pharmacol. 91:31–39. 2014. View Article : Google Scholar : PubMed/NCBI

35 

Zhang L, Niu T, Huang Y, Zhu H, Zhong W, Lin J and Zhang Y: Compound 331 selectively induces glioma cell death by upregulating miR-494 and downregulating CDC20. Sci Rep. 5:120032015. View Article : Google Scholar : PubMed/NCBI

36 

Wang L, Hou Y, Yin X, Su J, Zhao Z, Ye X, Zhou X, Zhou L and Wang Z: Rottlerin inhibits cell growth and invasion via down-regulation of Cdc20 in glioma cells. Oncotarget. 7:69770–69782. 2016.PubMed/NCBI

37 

Zeng X, Sigoillot F, Gaur S, Choi S, Pfaff KL, Oh DC, Hathaway N, Dimova N, Cuny GD and King RW: Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell. 18:382–395. 2010. View Article : Google Scholar : PubMed/NCBI

38 

Verma R, Peters NR, D'Onofrio M, Tochtrop GP, Sakamoto KM, Varadan R, Zhang M, Coffino P, Fushman D, Deshaies RJ and King RW: Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science. 306:117–120. 2004. View Article : Google Scholar : PubMed/NCBI

39 

Wu F, Dai X, Gan W, Wan L, Li M, Mitsiades N, Wei W, Ding Q and Zhang J: Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. Cancer Lett. 385:207–214. 2017. View Article : Google Scholar : PubMed/NCBI

40 

Wan L, Tan M, Yang J, Inuzuka H, Dai X, Wu T, Liu J, Shaik S, Chen G, Deng J, et al: APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. Dev Cell. 29:377–391. 2014. View Article : Google Scholar : PubMed/NCBI

41 

Zheng JH, Viacava Follis A, Kriwacki RW and Moldoveanu T: Discoveries and controversies in BCL-2 protein-mediated apoptosis. FEBS J. 283:2690–2700. 2016. View Article : Google Scholar : PubMed/NCBI

42 

O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S and Huang DC: Bim: A novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 17:384–395. 1998. View Article : Google Scholar : PubMed/NCBI

43 

U M, Miyashita T, Shikama Y, Tadokoro K and Yamada M: Molecular cloning and characterization of six novel isoforms of human Bim, a member of the proapoptotic Bcl-2 family. FEBS Lett. 509:135–141. 2001. View Article : Google Scholar : PubMed/NCBI

44 

Correia C, Lee SH, Meng XW, Vincelette ND, Knorr KL, Ding H, Nowakowski GS, Dai H and Kaufmann SH: Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochim Biophys Acta. 1853:1658–1671. 2015. View Article : Google Scholar : PubMed/NCBI

45 

Sionov RV, Vlahopoulos SA and Granot Z: Regulation of Bim in health and disease. Oncotarget. 6:23058–23134. 2015. View Article : Google Scholar : PubMed/NCBI

46 

Akiyama T, Dass CR and Choong PF: Bim-targeted cancer therapy: A link between drug action and underlying molecular changes. Mol Cancer Ther. 8:3173–3180. 2009. View Article : Google Scholar : PubMed/NCBI

47 

Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P, Villunger A, Adams JM and White E: Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell. 7:227–238. 2005. View Article : Google Scholar : PubMed/NCBI

48 

Simpson CD, Anyiwe K and Schimmer AD: Anoikis resistance and tumor metastasis. Cancer Lett. 272:177–185. 2008. View Article : Google Scholar : PubMed/NCBI

49 

Woods NT, Yamaguchi H, Lee FY, Bhalla KN and Wang HG: Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res. 67:10744–10752. 2007. View Article : Google Scholar : PubMed/NCBI

50 

Chen K, Tu Y, Zhang Y, Blair HC, Zhang L and Wu C: PINCH-1 regulates the ERK-Bim pathway and contributes to apoptosis resistance in cancer cells. J Biol Chem. 283:2508–2517. 2008. View Article : Google Scholar : PubMed/NCBI

51 

Iurlaro R and Muñoz-Pinedo C: Cell death induced by endoplasmic reticulum stress. FEBS J. 283:2640–2652. 2016. View Article : Google Scholar : PubMed/NCBI

52 

Savry A, Carre M, Berges R, Rovini A, Pobel I, Chacon C, Braguer D and Bourgarel-Rey V: Bcl-2-enhanced efficacy of microtubule-targeting chemotherapy through Bim overexpression: Implications for cancer treatment. Neoplasia. 15:49–60. 2013. View Article : Google Scholar : PubMed/NCBI

53 

Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Corrales-Rodriguez L, Martín C, Reguart N, et al: BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations. Oncotarget. 7:68933–68942. 2016. View Article : Google Scholar : PubMed/NCBI

54 

Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, et al: The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res. 20:2001–2010. 2014. View Article : Google Scholar : PubMed/NCBI

55 

Gambichler T, Rooms I, Scholl L, Stockfleth E, Stucker M and Sand M: BH3-only protein Bim predicts advanced stage of cutaneous melanoma. J Eur Acad Dermatol Venereol. 30:1926–1929. 2016.PubMed/NCBI

56 

Kim BW, Cho H, Ylaya K, Kitano H, Chung JY, Hewitt SM and Kim JH: Bcl-2-like protein 11 (BIM) expression is associated with favorable prognosis for patients with cervical cancer. Anticancer Res. 37:4873–4879. 2017.PubMed/NCBI

57 

Zhang L, Jiang T, Li X, Wang Y, Zhao C, Zhao S, Xi L, Zhang S, Liu X, Jia Y, et al: Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer. Cancer. 123:2927–2935. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

August 2018
Volume 40 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Gao, Y., Zhang, B., Wang, Y., & Shang, G. (2018). Cdc20 inhibitor apcin inhibits the growth and invasion of osteosarcoma cells. Oncology Reports, 40, 841-848. https://doi.org/10.3892/or.2018.6467
MLA
Gao, Y., Zhang, B., Wang, Y., Shang, G."Cdc20 inhibitor apcin inhibits the growth and invasion of osteosarcoma cells". Oncology Reports 40.2 (2018): 841-848.
Chicago
Gao, Y., Zhang, B., Wang, Y., Shang, G."Cdc20 inhibitor apcin inhibits the growth and invasion of osteosarcoma cells". Oncology Reports 40, no. 2 (2018): 841-848. https://doi.org/10.3892/or.2018.6467